You are here: Industry Insights > Pfizer

News List

Pfizer’s breast cancer drug combo falls short of survival goal financialexpress
June 29, 2018
Ibrance is Pfizer’s blockbuster treatment and is already approved as a combination with endocrine therapy for use in breast cancer patients
Price of Pfizer's smoking-cessation drug Chantix doubles in just 5 years fiercepharma
June 27, 2018
Pfizer’s smoking-cessation drug Chantix nudged closer to blockbuster status last year, bringing in $997 million in sales—up 18% from 2016.
In rare slip, Pfizer steamroller Ibrance fails to show it helps patients live longer biospectrumasia
June 26, 2018
More than two years ago, Pfizer’s Ibrance won an FDA nod to treat some breast cancer patients whose disease had progressed after endocrine therapy. But new study results suggest the drug may not actually help patients live longer.
Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness worldpharmanews
June 20, 2018
Pfizer Inc. will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025
Pfizer wins appeal against CMA fine over epilepsy drug price pharmaceutical-technology
June 13, 2018
US pharmaceutical giant Pfizer has won its appeal in the UK’s Competition Appeals Tribunal (CAT) against a £84.2m fine imposed by the Competition and Markets Authority (CMA) for dramatically increasing the price of its epilepsy drug, Epanutin.
Pfizer puts neuroscience at heart of new $600M VC fund fiercebiotech
June 11, 2018
Pfizer has committed $600 million to its VC fund. The Big Pharma is setting aside 25% of the money for investments in neuroscience startups, giving it a way to continue participating in the field despite its retreat from in-house R&D.
Pfizer to expand venture with $600 M investment biospectrumasia
June 07, 2018
In addition to increased funding, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical development.
Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine worldpharmanews
June 05, 2018
Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways
Pfizer's Xalkori receives FDA breakthrough therapy designation biospectrumasia
June 01, 2018
If approved in patients with metastatic NSCLC with MET exon 14 alterations, XALKORI will be the only TKI with demonstrated efficacy in three separate biomarker-driven indications in NSCLC.
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene fiercepharma
May 30, 2018
With Pfizer’s Xeljanz snapping up new indications and AbbVie’s upadacitinib on the way, makers of anti-inflammatory drugs will soon feel the heat from JAK inhibitors if they haven't already. But some will feel it more than others, Bernstein analysts say.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page